Alkermes plc (NASDAQ:ALKS) and Matinas BioPharma Holdings Inc. (NYSEAMERICAN:MTNB) compete with each other in the Biotechnology sector. We will analyze and contrast their dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership.
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Alkermes plc | 21 | 63.42 | 155.25M | -1.17 | 0.00 |
| Matinas BioPharma Holdings Inc. | 1 | 0.00 | 137.75M | -0.15 | 0.00 |
In table 1 we can see Alkermes plc and Matinas BioPharma Holdings Inc.’s gross revenue, earnings per share and valuation.
Profitability
Table 2 shows us the return on assets, return on equity and net margins of both companies.
| Net Margins | Return on Equity | Return on Assets | |
| Alkermes plc | 737,880,228.14% | -16.2% | -10.3% |
| Matinas BioPharma Holdings Inc. | 20,658,368,326.33% | -157.2% | -59.6% |
Volatility & Risk
A 1.78 beta indicates that Alkermes plc is 78.00% more volatile compared to Standard & Poor’s 500. Matinas BioPharma Holdings Inc. has a 1.73 beta and it is 73.00% more volatile than Standard & Poor’s 500.
Liquidity
The Current Ratio and Quick Ratio of Alkermes plc are 3 and 2.7 respectively. Its competitor Matinas BioPharma Holdings Inc.’s Current Ratio is 12.8 and its Quick Ratio is 12.8. Matinas BioPharma Holdings Inc. can pay off short and long-term obligations better than Alkermes plc.
Analyst Recommendations
The Ratings and Recommendations for Alkermes plc and Matinas BioPharma Holdings Inc. are featured in the next table.
| Sell Ratings | Hold Ratings | Buy Ratings | Rating Score | |
| Alkermes plc | 0 | 4 | 0 | 2.00 |
| Matinas BioPharma Holdings Inc. | 0 | 0 | 0 | 0.00 |
The upside potential is 60.15% for Alkermes plc with average price target of $29.5.
Institutional & Insider Ownership
Institutional investors owned 99.2% of Alkermes plc shares and 25.8% of Matinas BioPharma Holdings Inc. shares. Insiders owned roughly 0.7% of Alkermes plc’s shares. Comparatively, 1.9% are Matinas BioPharma Holdings Inc.’s share owned by insiders.
Performance
In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
| Performance (W) | Performance (M) | Performance (Q) | Performance (HY) | Performance (Y) | Performance (YTD) | |
| Alkermes plc | 1.18% | 1.36% | -18.74% | -29.39% | -47.26% | -21.52% |
| Matinas BioPharma Holdings Inc. | 3.84% | -5.27% | -18.89% | -17.23% | 114.58% | 36.32% |
For the past year Alkermes plc has -21.52% weaker performance while Matinas BioPharma Holdings Inc. has 36.32% stronger performance.
Summary
On 6 of the 11 factors Alkermes plc beats Matinas BioPharma Holdings Inc.
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products that are designed to address unmet medical needs of patients in various therapeutic areas worldwide. The companyÂ’s marketed products include ARISTADA (aripiprazole lauroxil) for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) for the treatment of type 2 diabetes. It is also developing ALKS 5461 that is in Phase III clinical trials for the treatment of depressive disorder; ALKS 3831, which is in Phase III clinical trials to treat schizophrenia; ALKS 8700, a monomethyl fumarate molecule, which is in Phase III clinical trials to treat multiple sclerosis; ALKS 6428, which is in Phase III clinical trials to help physicians transition patients from physical dependence on opioids; and Aripiprazole lauroxil, an injectable atypical antipsychotic, which has completed a Phase I clinical trials for the treatment of schizophrenia, as well as ALKS 4230, a cell activator that is in Phase I clinical trials for cancer immunotherapy. The company serves pharmaceutical wholesalers, and specialty pharmacies and distributors. It has collaboration agreements with Ortho-McNeil-Janssen Pharmaceuticals, Inc. and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing therapeutics for the treatment of fungal and bacterial infections. The company develops orally delivered therapeutics based on a proprietary, lipid-based drug delivery platform called cochleate delivery technology. Its lead product candidate is MAT 2203, an orally-administered cochleate formulation of the broad spectrum anti-fungal drug amphotericin B that is in Phase II study for the treatment of fungal infections. The company is also involved in developing MAT2501, an orally-administered, encochleated formulation of aminoglycoside antibiotic agent amikacin for acute bacterial infections, including non-tuberculous mycobacterium (NTM) and multi-drug resistant gram negative bacterial infections. In addition, it is exploring strategic partnership options for MAT8800 discovery program, which intends to identify product candidates derived from omega-3 fatty acids for the treatment of non-alcoholic fatty liver disease. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
